161 related articles for article (PubMed ID: 34820328)
1. Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review.
Chen C; Zhang W; Zhou D; Zhang Y
Front Oncol; 2021; 11():757403. PubMed ID: 34820328
[TBL] [Abstract][Full Text] [Related]
2. Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review.
Yan Z; Yao S; Liu Y; Zhang J; Li P; Wang H; Chu J; Zhao S; Yao Z
Front Oncol; 2020; 10():608304. PubMed ID: 33363038
[TBL] [Abstract][Full Text] [Related]
3. Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy.
Hao YY; Chen PP; Yuan XG; Zhao AQ; Liang Y; Liu H; Qian WB
World J Clin Cases; 2022 Jul; 10(19):6555-6562. PubMed ID: 35979312
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma.
Graf SA; Cassaday RD; Morris K; Voutsinas JM; Wu QV; Behnia S; Lynch RC; Krakow E; Rasmussen H; Chauncey TR; Kanan S; Soma L; Smith SD; Gopal AK
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):176-181. PubMed ID: 33358575
[TBL] [Abstract][Full Text] [Related]
5. Case Report: Outcome and Adverse Events of Anti-PD-1 Antibody Plus Chidamide for Relapsed/Refractory Sézary Syndrome: Case Series and A Literature Review.
Chen C; Liu Z; Liu J; Zhang W; Zhou D; Zhang Y
Front Oncol; 2022; 12():842123. PubMed ID: 35387123
[TBL] [Abstract][Full Text] [Related]
6. Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.
Tian C; Chen Z; Li Y
J Int Med Res; 2020 Jul; 48(7):300060520936053. PubMed ID: 32643971
[TBL] [Abstract][Full Text] [Related]
7. Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases.
Du L; Zhang L; Li L; Li X; Yan J; Wang X; Fu X; Sun Z; Zhang X; Li Z; Wu J; Yu H; Chang Y; Zhou Z; Nan F; Wu X; Tian L; Zhang M
Onco Targets Ther; 2020; 13():7189-7197. PubMed ID: 32801749
[TBL] [Abstract][Full Text] [Related]
8. CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma.
Sun Y; Gao Y; Chen J; Huang L; Deng P; Chen J; Chai KXY; Hong JH; Chan JY; He H; Wang Y; Cheah D; Lim JQ; Chia BKH; Huang D; Liu L; Liu S; Wang X; Teng Y; Pang D; Grigoropoulos NF; Teh BT; Yu Q; Lim ST; Li W; Ong CK; Huang H; Tan J
Cancer Lett; 2021 Sep; 521():268-280. PubMed ID: 34481935
[TBL] [Abstract][Full Text] [Related]
9. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
[TBL] [Abstract][Full Text] [Related]
10. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
Guan XW; Wang HQ; Ban WW; Chang Z; Chen HZ; Jia L; Liu FT
Cell Death Dis; 2020 Jan; 11(1):20. PubMed ID: 31907371
[TBL] [Abstract][Full Text] [Related]
11. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
12. A case report of synchronous triple primary malignancies: Diffuse large B-cell lymphoma, rectal adenocarcinoma and hepatocellular carcinoma.
Qiu B; Lin C; Wu L; Li Y
Front Oncol; 2022; 12():1046878. PubMed ID: 36620610
[TBL] [Abstract][Full Text] [Related]
13. Successful Treatment of Chidamide and Cyclosporine for Refractory/Relapsed Angioimmunoblastic T Cell Lymphoma With Evans Syndrome: A Case Report With Long-Term Follow-Up.
Zhu F; Li Q; Pan H; Xiao Y; Liu T; Liu X; Li J; Wu G; Zhang L
Front Oncol; 2020; 10():1725. PubMed ID: 32984055
[TBL] [Abstract][Full Text] [Related]
14. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
Shi Y; Jia B; Xu W; Li W; Liu T; Liu P; Zhao W; Zhang H; Sun X; Yang H; Zhang X; Jin J; Jin Z; Li Z; Qiu L; Dong M; Huang X; Luo Y; Wang X; Wang X; Wu J; Xu J; Yi P; Zhou J; He H; Liu L; Shen J; Tang X; Wang J; Yang J; Zeng Q; Zhang Z; Cai Z; Chen X; Ding K; Hou M; Huang H; Li X; Liang R; Liu Q; Song Y; Su H; Gao Y; Liu L; Luo J; Su L; Sun Z; Tan H; Wang H; Wang J; Wang S; Zhang H; Zhang X; Zhou D; Bai O; Wu G; Zhang L; Zhang Y
J Hematol Oncol; 2017 Mar; 10(1):69. PubMed ID: 28298231
[TBL] [Abstract][Full Text] [Related]
15. Phenotype profiling of primary testicular diffuse large B-cell lymphomas.
Menter T; Ernst M; Drachneris J; Dirnhofer S; Barghorn A; Went P; Tzankov A
Hematol Oncol; 2014 Jun; 32(2):72-81. PubMed ID: 23949965
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma: A case report and literature review.
Jin J; Zheng C; Wu S
Medicine (Baltimore); 2018 Jan; 97(2):e9611. PubMed ID: 29480865
[TBL] [Abstract][Full Text] [Related]
17. Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report.
Wang XT; Guo W; Sun M; Han W; Du ZH; Wang XX; Du BB; Bai O
World J Clin Cases; 2020 Jul; 8(14):3122-3129. PubMed ID: 32775395
[TBL] [Abstract][Full Text] [Related]
18. Chidamide based combination regimen for treatment of monomorphic epitheliotropic intestinal T cell lymphoma following radical operation: Two case reports.
Liu TZ; Zheng YJ; Zhang ZW; Li SS; Chen JT; Peng AH; Huang RW
World J Clin Cases; 2020 Apr; 8(7):1278-1286. PubMed ID: 32337203
[TBL] [Abstract][Full Text] [Related]
19. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
